Skip to content
Menu

Morgan Stanley Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $12

Benzinga Newsdesk 3 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Morgan Stanley analyst Sean Laaman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $13 to $12.

Morgan Stanley analyst Sean Laaman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $13 to $12.

Read at benzinga.com

← All stock news